What is Brookline Cap M’s Estimate for MRKR Q2 Earnings?

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Investment analysts at Brookline Cap M issued their Q2 2026 earnings per share (EPS) estimates for shares of Marker Therapeutics in a research note issued on Wednesday, March 18th. Brookline Cap M analyst L. Cann forecasts that the company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.17. The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative return on equity of 84.13% and a negative net margin of 343.03%.

A number of other analysts also recently weighed in on the stock. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright started coverage on Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price target for the company. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Marker Therapeutics Stock Performance

Shares of MRKR opened at $1.32 on Friday. The company’s fifty day moving average is $1.60 and its 200 day moving average is $1.29. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.07. The stock has a market capitalization of $22.00 million, a PE ratio of -1.55 and a beta of 1.42.

Institutional Investors Weigh In On Marker Therapeutics

Hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new position in shares of Marker Therapeutics during the 4th quarter worth $222,000. XTX Topco Ltd lifted its stake in Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after acquiring an additional 36,269 shares during the period. Osaic Holdings Inc. increased its position in Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after purchasing an additional 13,340 shares during the period. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics in the 4th quarter valued at about $60,000. Finally, Renaissance Technologies LLC lifted its position in shares of Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the period. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.